Maribavir for kids with CMV after transplant
Treatments studied
Part of Blood & lymphatic, Infections clinical trials.
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 years old, and a parent/guardian must consent and the child should assent when appropriate
- You must have had a functioning transplant (either stem cell transplant or solid organ transplant) at screening
- You must have CMV infection confirmed by blood tests that meet specific “virus level” thresholds on two tests
- Blood and kidney tests must be high enough (neutrophils, platelets, hemoglobin, and kidney function)
- You must test negative for HIV within 3 months of starting the study
- You must be able to take the study medicine by mouth and follow study rules for about 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.
This study tests a medicine called maribavir for people who have a cytomegalovirus infection after a stem cell transplant. It aims to see if the drug safely clears the virus.
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
Hear when a new Cytomegalovirus (CMV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.